


PHARMACEUTICAL 2017

M BeiGene

BeiGene Ltd. Rank 93 of 313



PHARMACEUTICAL 2017

BeiGene Ltd. Rank 93 of 313



The relative strengths and weaknesses of BeiGene Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BeiGene Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 268% points. The greatest weakness of BeiGene Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is -41%, being 376% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	374,399
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	35,058
Liabilities, Non-Current	17,848
Other Assets	5,437
Other Compr. Net Income	863
Other Expenses	54
Other Liabilities	0
Other Net Income	-2,103
Property and Equipment	25,977
Research and Development	98,033
Revenues	1,070
Selling, General and Administrative Expense	20,097

Output Variable	Value in 1000 USD
Assets	405,813
Liabilities	52,906
Expenses	118,184
Stockholders Equity	352,907
Net Income	-119,217
Comprehensive Net Income	-118,786
Economic Capital Ratio	-41%